The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes.
Ronald B GoldbergNeil J StoneScott M GrundyPublished in: Diabetes care (2021)
The American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines recently published its 2018 recommendations on management of LDL cholesterol (LDL-C) in people with diabetes. For primary prevention, moderate-intensity statin therapy is recommended for those aged 40-75 years, with a preference for high-intensity statin treatment for older subjects and for those with higher estimated risk or risk-enhancing factors following a patient-clinician discussion. Statin therapy may be reasonable in adults <40 years or >75 years of age where there is less evidence for benefit. For people with diabetes and established atherosclerotic cardiovascular disease, high-intensity statin therapy is recommended. The majority of these subjects have very high risk, and an LDL-C goal of <70 mg/dL is recommended. If this target is not achieved, ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor may be added.
Keyphrases
- high intensity
- low density lipoprotein
- cardiovascular disease
- type diabetes
- resistance training
- coronary artery disease
- glycemic control
- cardiovascular events
- cardiovascular risk factors
- clinical practice
- atrial fibrillation
- case report
- adipose tissue
- stem cells
- randomized controlled trial
- physical activity
- metabolic syndrome
- mesenchymal stem cells
- cardiac surgery
- systematic review
- replacement therapy